ProfileGDS5678 / 1429156_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 71% 72% 67% 75% 72% 70% 67% 70% 70% 74% 75% 73% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7339273
GSM967853U87-EV human glioblastoma xenograft - Control 24.5138871
GSM967854U87-EV human glioblastoma xenograft - Control 34.6474572
GSM967855U87-EV human glioblastoma xenograft - Control 44.1213767
GSM967856U87-EV human glioblastoma xenograft - Control 54.9942375
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5178272
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3509370
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0382167
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3769570
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3886870
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7769374
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9573375
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7247773
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5344672